SARS-CoV-2, a recently emerged zoonotic virus, has resulted in unstoppable high morbidity and mortality rates worldwide. However, due to a limited knowledge of the dynamics of the SARS-CoV-2 infection, it has been observed that the current COVID-2019 therapy has led to some clinical repercussions. We discuss the adverse effects of drugs for COVID-2019 primarily based on some clinical trials. As therapeutic efficacy and toxicity of therapy may vary due to different, genetic determinants, sex, age and the ethnic background of test subjects, hence biomarker-based personalized therapy could be more appropriate. We will share our thoughts on the current landscape of personalized therapy as a roadmap to fight against SARS-CoV-2 or another emerging pathogen.
【저자키워드】 COVID-19, Drug repurposing, SARS-CoV-2, Biomarkers, antivirals, drugs, adverse effects, Personalized medicine, drug toxicity, precision therapy, 【초록키워드】 therapy, Biomarker, knowledge, SARS-COV-2 infection, Infection, clinical trials, Sex, Toxicity, drug, virus, COVID-2019, adverse effects, pathogen, zoonotic, age, morbidity and mortality, mortality rates, genetic determinants, adverse effect, therapeutic efficacy, thought, subjects,